Levetiracetam Neogen (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action reduces neuronal hyper‑excitability and helps prevent the spread of epileptic activity without directly influencing ion channels or GABA receptors.

The dosage of Levetiracetam Neogen is determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Only a qualified healthcare professional should set the appropriate dose and infusion rate.

Safety data for levetiracetam in pregnancy and lactation are limited. The prescriber should evaluate the potential benefits against possible risks and discuss these considerations with the patient before initiating therapy.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Levetiracetam has a distinct mechanism (SV2A binding) and a relatively favorable interaction profile compared with enzyme‑inducing agents like carbamazepine. It is often chosen for patients who need rapid intravenous control and for those who may experience fewer drug‑drug interactions.

Store the product at ambient temperature, below 25 °C, in its original container. Protect it from moisture and direct sunlight. Do not freeze the solution, and ensure the vial is kept upright to avoid contamination.

Levetiracetam Neogen is given by intravenous infusion. The exact infusion rate and duration are set by the treating physician, who will follow institutional protocols and monitor the patient for efficacy and tolerability.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, suicidal thoughts or severe depression, blood dyscrasias, and anaphylactic reactions. Patients should be monitored closely for any signs of these conditions, and treatment should be stopped if they occur.

Patients with known hypersensitivity to levetiracetam or any component of the formulation should avoid its use. Caution is also advised for individuals with severe renal impairment unless dose adjustments are made, and for those with a history of serious psychiatric disorders.